National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Subcutaneous Abatacept (Orencia®) in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor.

Rapid Review

Commenced Completed Outcome
28/11/2012 21/12/2012 Full Pharmacoeconomic Assessment Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
02/07/2013  11/11/2013 Reimbursement not recommended at the submitted price

Summary

November 2015

The HSE has approved reimbursement following confidential price negotiations.